Job Description

For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we'll help you build a career that you can feel passionate about.
Job Summary
At our world class facility in Elphinstone, Tranent (close to Edinburgh), our Report Centre currently has an exciting career opportunity for an Assistant Report Publisher.
Due to our continued growth and success, we can offer rewarding opportunities in a research environment. The Assistant Report Publisher will produce scientific reports to meet Sponsor and regulatory standards and ensure issue of reports in line with protocol deadlines.
Key Responsibilities:

• To compile and publish reports using Charles River and Sponsors' own templates to conform to Sponsor and regulatory requirements using Adlib publishing system, MS Word, Adobe Acrobat and associated publishing tools
• To format check and pdf phase reports from internal contributing areas according to ensure regulatory compliance
• Ensure that all reports are of a high standard by checking of own work before the QC process
• Ship reports to clients to meet deadlines

Applicants should have:

• Proven excellent skills in Microsoft Word and Adobe - able to format, apply and modify styles, tables of contents and hyperlinks
• Detail oriented with a good eye for how text and graphics look
• Ability to work within a pressured environment and to tight deadlines
• Good, confident communication and people skills which enable you to effectively collaborate with internal/external employees of all levels
• Ability to work independently

The salary for this role is 25,352.56.
About Safety Assessment
Charles River is committed to helping our partners expedite their preclinical drug development with exceptional safety assessment services, state-of-the-art facilities and expert regulatory guidance. From individual specialty toxicology and IND enabling studies to tailored packages and total laboratory support, our deeply experienced team can design and execute programs that anticipate challenges and avoid roadblocks for a smooth, efficient journey to market. Each year approximately 300 investigational new drug (IND) programs are conducted in our Safety Assessment facilities.
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients' clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 17,000 employees within 90 facilities in 20 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client's unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2019, revenue increased to $2.62 billion.
At Charles River, we are passionate about our role in improving the quality of people's lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~85% of the drugs approved by the FDA in 2019.

Skills Required